The author replies:
To the Editor:
Dr. Hellstrom's theories about vasospasm, although unproven, are interesting and provocative. I would certainly agree that further investigation of the role of such a mechanism in the pathogenesis of acute myocardial infarction is warranted. However, I would like to make it clear that our experimental model' was not devised to determine the precise mechanisms of action of nitroglycerin in acute myocardial infarction and that the salutary effects of nitroglycerin we observed (with arterial pressure held constant by simultaneous administration of methoxamine) can be explained by "peripheral" actions, by "-central" actions (not necessarily relief of vasospasm), or, more likely, by a combination of the two.
For example, we found in the experimental animal that nitroglycerin administered alone consistently diminishes left ventricular filling pressure, an effect only partially reversed when methoxamine is administered simultaneously at a rate to prevent nitroglycerin-induced hypotension (unpublished observations). These findings suggest that nitroglycerininduced venodilatation is not fully reversed by doses of methoxamine that completely reverse the effects of nitroglycerin on the arterial system. Thus, if the decrease in filling pressure reflects a decrease in left ventricular volume, myocardial wall tension (and thereby MVO2) would diminish even if arterial pressure were maintained constant by methoxamine infusion. Such a change would lead to a diminution of ischemia caused by acute coronary occlusion. Apart from any influence on MVO2, it also is possible that nitroglycerin diminishes ischemia in our preparation by increasing flow to ischemic myocardiumnot by dilating coronary arteries in spasm (an unlikely consequence of mechanical occlusion of the proximal segment of the artery) -but by reducing resistance to coronary collateral flow. This could be accomplished by two actions of nitroglycerin. Collateral flow or flow within the ischemic bed during diastole could be increased indirectly by nitroglycerininduced diminution in ventricular diastolic volume and pressure; the consequent decrease in wall tension would diminish resistance to flow through collateral channels and ischemic capillary beds. In addition, a direct vasodilator action of nitroglycerin on human coronary collateral channels was demonstrated recently by intraoperative studies of patients at the time of coronary artery bypass.'
Finally, although Dr. Hellstrom has cited his own studies as substantiating a vasospasm mechanism during acute myocardial infarction, his data also can be explained by well-known autoregulatory mechanisms, rather than vasospasm.
In summary, I do not contend that vasospasm is not involved in the complex sequence of events occurring during acute myocardial infarction. Indeed, vasospasm may be an important mechanism in the rare 'patient with "variant" angina who goes on to infarct and is found to have normal coronary arteries. However, the purpose of my reply to Dr. Hellstrom's letter is to point out that 1) our results with nitroglycerin can be entirely explained without invoking relief of vasospasm, 2) no experimental data yet published proves the existence of vasospasm during myocardial infarction, and 3) with the above rare exception, no clinical data can be pointed to which suggest that vasospasm is an important cause of acute myocardial infarction in man. 
